Sugi Predict

Sugi Predict / Targets / EPHX1

EPHX1

Epoxide hydrolase 1 · P07099 · EPHX1 on Sugi Atlas →

260,522 patent compounds predicted against EPHX1, 142,647 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
1,3-Dicyclohexylurea 1,3-Dicyclohexylurea (SCHEMBL2755) 1.00 14/20
SCHEMBL9390 SCHEMBL9390 0.95 12/20
SCHEMBL35191 SCHEMBL35191 0.70 12/20
SCHEMBL35650 SCHEMBL35650 0.53 12/20
SCHEMBL35651 SCHEMBL35651 0.53 12/20
SCHEMBL37597 SCHEMBL37597 0.52 11/20
SCHEMBL37783 SCHEMBL37783 0.52 11/20
SCHEMBL37592 SCHEMBL37592 0.50 10/20
SCHEMBL41714 SCHEMBL41714 0.50 10/20
SCHEMBL45893 SCHEMBL45893 0.47 10/20
SCHEMBL60196 SCHEMBL60196 0.66 9/20
SCHEMBL25793 SCHEMBL25793 0.59 9/20
SCHEMBL36870 SCHEMBL36870 0.59 9/20
Dodine Dodine (SCHEMBL22124) 0.55 9/20
Dodine Dodine (SCHEMBL21643) 0.54 9/20
SCHEMBL38478 SCHEMBL38478 0.55 8/20
SCHEMBL39683 SCHEMBL39683 0.55 8/20
SCHEMBL45417 SCHEMBL45417 0.55 8/20
SCHEMBL36903 SCHEMBL36903 0.50 8/20
SCHEMBL36904 SCHEMBL36904 0.50 8/20

Clinical trials — most relevant to EPHX1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans PHASE4COMPLETED
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Effectiveness of Vitamin D in Primary Dysmenorrhoea PHASE3COMPLETED
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study) PHASE1/PHASE2RECRUITING
Prostaglandin Inhibition for Emphysema PHASE2COMPLETED
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure PHASE2COMPLETED
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects PHASE1COMPLETED
Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects PHASE1COMPLETED
Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Effects of Miconazole on Blood Flow PHASE1COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function nanCOMPLETED
Blood Vessel Study nanCOMPLETED
Eicosanoids in Human Heart Failure nanUNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A nanACTIVE_NOT_RECRUITING
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression nanCOMPLETED
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension nanRECRUITING
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions nanRECRUITING
Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses nanCOMPLETED
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm nanCOMPLETED
Genetic and Environmental Risk Factors Related to Esophageal Cancer nanACTIVE_NOT_RECRUITING
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia nanRECRUITING
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study nanCOMPLETED
Genetics and Cardiovascular Reactivity in Young Twins nanCOMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a EPHX1 binder may also engage these)

ProteinNameSimilarity
Q9D379 — 1.000 Q9D379 →
P79381 — 1.000 P79381 →
P07687 — 0.997 P07687 →
P04068 — 0.996 P04068 →
A5A6K6 — 0.959 A5A6K6 →
Q4R3Y4 — 0.958 Q4R3Y4 →
Q8BMF3 — 0.957 Q8BMF3 →
FUCA2 Plasma alpha-L-fucosidase 0.957 landscape →
Q64323 — 0.957 Q64323 →
Q8CIG8 — 0.956 Q8CIG8 →
Q66IG4 — 0.956 Q66IG4 →
PRMT5 Protein arginine N-methyltransferase 5 0.956 landscape →
A2APY7 — 0.956 A2APY7 →
GLS2 Glutaminase liver isoform, mitochondrial 0.956 landscape →
Q6U6J0 — 0.956 Q6U6J0 →
Q70VZ8 — 0.956 Q70VZ8 →
Q6GQL1 — 0.956 Q6GQL1 →
B4G0F3 — 0.955 B4G0F3 →
Q5R698 — 0.955 Q5R698 →
ME3 NADP-dependent malic enzyme, mitochondrial 0.955 landscape →
Q9EPB5 — 0.955 Q9EPB5 →
Q9UN36 — 0.955 Q9UN36 →
Q08C93 — 0.955 Q08C93 →
ALG1 Chitobiosyldiphosphodolichol beta-mannosyltransferase 0.955 landscape →
Q4R5M3 — 0.955 Q4R5M3 →
O35409 — 0.955 O35409 →
P93732 — 0.955 P93732 →
Q5RBN6 — 0.955 Q5RBN6 →
A3KP37 — 0.954 A3KP37 →
Q5RFI5 — 0.954 Q5RFI5 →